Furthermore, related researches have proved that upregulated ROS could abrogate JAK2/STAT3 signaling to suppress tumor growth in cancers such as hepatocellular carcinoma [44], multiple myeloma [45], and colorectal cancer [46, 47]. This evidence concerns the gene JAK2 and plasma cell myeloma.